This trial is testing a new cancer drug to see if it's more effective than the current standard of care for treating follicular lymphoma.
- Follicular Lymphoma
1 Primary · 4 Secondary · Reporting Duration: Up to 3 years
Side Effects for
1 Treatment Group
Loncastuximab tesirine + Rituximab
1 of 1
39 Total Participants · 1 Treatment Group
Primary Treatment: Loncastuximab tesirine · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 24 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What therapeutic applications is Loncastuximab tesirine typically employed for?
"Loncastuximab tesirine is the recommended treatment for diffuse large b-cell lymphoma (DLBCL). However, it has been found efficacious in combatting relapsed large B cell lymphomas, other B-cell neoplasms and polyangiitis." - Anonymous Online Contributor
Are new participants being enrolled in this research endeavor?
"If the information on clinicaltrials.gov is accurate, then this medical trial is presently recruiting patients. It was first announced on February 11th 2022 and its details were last amended on July 11th of the same year." - Anonymous Online Contributor
What is the current participant recruitment rate of this clinical trial?
"Affirmative, the information provided on clinicaltrials.gov confirms that this medical experiment is actively enrolling participants. This research was first posted on 2/11/2022 and has been recently modified on 7/11/2022; 39 patients need to be recruited from 1 hospital setting." - Anonymous Online Contributor
How securely does Loncastuximab tesirine protect patients from harm?
"While Loncastuximab tesirine has not demonstrated efficacy in clinical trials, there is some safety data to suggest that it should receive a score of 2." - Anonymous Online Contributor